Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

Inclusion Criteria: * Male or female subjects, who are \> or = 18 and \< or = 65 years of age at the time of screening * Subject has provided informed consent prior to initiation of any study-specific activities/procedures * Women must be of non-reproductive potential (ie, postmenopausal, history of hysterectomy, or history of bilateral oophorectomy) * Men must agree to practice an acceptable method of effective birth control while on study through 11 weeks after receiving the dose of study drug. * Men must be willing to abstain from sperm donation while on study through 11 weeks after receiving the dose of study drug * Body Mass Index \> or = 18 and \< or = 38 kg/m\^2 at screening * Physical examination and 12-lead electrocardiograms (ECGs) are clinically acceptable to the investigator * Non-hypertensive subjects or subjects with treated, stable hypertension as defined by blood pressure not exceeding 170/100 mm Hg as an average during screening and day -1; for subjects with renal impairment, no change in dosage and medication for \> or = 4 weeks prior to screening, and expected to remain on this dose and medication for the entire duration of the study * Willing to maintain current general diet and physical activity regimen * Renal function in 1 of the following 2 categories at the time of screening: Group 1 - Severe Renal Impairment (eGFR 15 to 29 mg/min/1.73 m\^2) and not anticipated to require hemodialysis or renal transplantation, and anticipated to have renal function a…